SamaCare has been named No. 14 in the Healthcare category on Fast Company’s 2026 Most Innovative Companies list.
You can view the full list here:
https://www.fastcompany.com/most-innovative-companies/list
Check out why here: https://www.fastcompany.com/91497221/healthcare-most-innovative-companies-2026
We see this recognition as validation of a broader shift happening in healthcare, one that leverages AI to do things AI is good at: simplify complex processes, harness knowledge, and reduce uncertainty to achieve better outcomes.
Prior authorization has become one of the most consequential barriers in modern healthcare. It delays treatment and consumes providers’ time. Too often, prior authorization prevents patients from starting therapies their physicians have already determined are clinically appropriate.
Prior authorization complexity is a systemic issue.
Physicians report that prior authorization contributes directly to delays in care and treatment abandonment. Patients experience those delays as uncertainty, frustration, and in many cases, worsening outcomes.
At its core, the problem is not just complexity, it’s opacity. Each payer has different requirements. Each therapy has different rules. The reasons behind denials or delays are often unclear, inconsistent, and difficult to predict. Denials are even delivered in vastly different formats (one of those sneaky “backend” challenges we had to solve in building SamaCare). For years, this lack of visibility has limited what healthcare stakeholders can actually do to reduce administrative delays that keep patients from treatment.
SamaCare has focused on a simple but powerful idea:
If you can see where patients fall out of the script-to-therapy journey, and why, you can fix it.
Today, SamaCare aggregates and analyzes real-world data from over 2 million prior authorizations across a network of more than 30,000 providers, spanning 97% of U.S. payers. This creates a level of visibility into patient access that has historically not existed. Instead of relying on lagging indicators like claims data, stakeholders can now understand access barriers as they happen, inside provider workflows.
Data alone does not improve patient access. Action does. Over the last 12 months, SamaCare has focused on embedding intelligence directly into the workflows where prior authorizations are created, submitted, and managed.
This includes:
For pharmaceutical market access teams, it also means something new: the ability to move from reactive support programs to targeted, data-driven interventions.
Instead of asking “where are we seeing issues?” after the fact, teams can now identify root causes in near real time and deploy support where it will have the greatest impact. Because the reality is, every delayed prior authorization is a human suffering, instead of starting treatment.
When administrative friction is reduced, the impact is measurable:
These are operational metrics, but they represent something more important: patients starting treatment sooner, staying on therapy, and avoiding the health consequences of delay.
Healthcare is entering a period defined by two opposing forces.
Without intervention, those forces pull in opposite directions.
SamaCare’s approach is to rebalance the system by focusing on the administrative layer, removing the friction that prevents prior authorization decisions from being carried out.
Being named to Fast Company’s Most Innovative Companies list is an incredible honor, but our work is far from done. The administrative barriers that exist between prescription and treatment are still one of the least visible, and most solvable, challenges in healthcare.
Our focus remains the same:
Innovation in healthcare can’t stop at the development of a therapy, it should extend all the way to ensuring that patients actually receive it.
SamaCare has been named No. 14 in the Healthcare category on Fast Company’s 2026 Most Innovative Companies list.
You can view the full list here:
https://www.fastcompany.com/most-innovative-companies/list
Check out why here: https://www.fastcompany.com/91497221/healthcare-most-innovative-companies-2026
We see this recognition as validation of a broader shift happening in healthcare, one that leverages AI to do things AI is good at: simplify complex processes, harness knowledge, and reduce uncertainty to achieve better outcomes.
Prior authorization has become one of the most consequential barriers in modern healthcare. It delays treatment and consumes providers’ time. Too often, prior authorization prevents patients from starting therapies their physicians have already determined are clinically appropriate.
Prior authorization complexity is a systemic issue.
Physicians report that prior authorization contributes directly to delays in care and treatment abandonment. Patients experience those delays as uncertainty, frustration, and in many cases, worsening outcomes.
At its core, the problem is not just complexity, it’s opacity. Each payer has different requirements. Each therapy has different rules. The reasons behind denials or delays are often unclear, inconsistent, and difficult to predict. Denials are even delivered in vastly different formats (one of those sneaky “backend” challenges we had to solve in building SamaCare). For years, this lack of visibility has limited what healthcare stakeholders can actually do to reduce administrative delays that keep patients from treatment.
SamaCare has focused on a simple but powerful idea:
If you can see where patients fall out of the script-to-therapy journey, and why, you can fix it.
Today, SamaCare aggregates and analyzes real-world data from over 2 million prior authorizations across a network of more than 30,000 providers, spanning 97% of U.S. payers. This creates a level of visibility into patient access that has historically not existed. Instead of relying on lagging indicators like claims data, stakeholders can now understand access barriers as they happen, inside provider workflows.
Data alone does not improve patient access. Action does. Over the last 12 months, SamaCare has focused on embedding intelligence directly into the workflows where prior authorizations are created, submitted, and managed.
This includes:
For pharmaceutical market access teams, it also means something new: the ability to move from reactive support programs to targeted, data-driven interventions.
Instead of asking “where are we seeing issues?” after the fact, teams can now identify root causes in near real time and deploy support where it will have the greatest impact. Because the reality is, every delayed prior authorization is a human suffering, instead of starting treatment.
When administrative friction is reduced, the impact is measurable:
These are operational metrics, but they represent something more important: patients starting treatment sooner, staying on therapy, and avoiding the health consequences of delay.
Healthcare is entering a period defined by two opposing forces.
Without intervention, those forces pull in opposite directions.
SamaCare’s approach is to rebalance the system by focusing on the administrative layer, removing the friction that prevents prior authorization decisions from being carried out.
Being named to Fast Company’s Most Innovative Companies list is an incredible honor, but our work is far from done. The administrative barriers that exist between prescription and treatment are still one of the least visible, and most solvable, challenges in healthcare.
Our focus remains the same:
Innovation in healthcare can’t stop at the development of a therapy, it should extend all the way to ensuring that patients actually receive it.
SamaCare has been named No. 14 in the Healthcare category on Fast Company’s 2026 Most Innovative Companies list.
You can view the full list here:
https://www.fastcompany.com/most-innovative-companies/list
Check out why here: https://www.fastcompany.com/91497221/healthcare-most-innovative-companies-2026
We see this recognition as validation of a broader shift happening in healthcare, one that leverages AI to do things AI is good at: simplify complex processes, harness knowledge, and reduce uncertainty to achieve better outcomes.
Prior authorization has become one of the most consequential barriers in modern healthcare. It delays treatment and consumes providers’ time. Too often, prior authorization prevents patients from starting therapies their physicians have already determined are clinically appropriate.
Prior authorization complexity is a systemic issue.
Physicians report that prior authorization contributes directly to delays in care and treatment abandonment. Patients experience those delays as uncertainty, frustration, and in many cases, worsening outcomes.
At its core, the problem is not just complexity, it’s opacity. Each payer has different requirements. Each therapy has different rules. The reasons behind denials or delays are often unclear, inconsistent, and difficult to predict. Denials are even delivered in vastly different formats (one of those sneaky “backend” challenges we had to solve in building SamaCare). For years, this lack of visibility has limited what healthcare stakeholders can actually do to reduce administrative delays that keep patients from treatment.
SamaCare has focused on a simple but powerful idea:
If you can see where patients fall out of the script-to-therapy journey, and why, you can fix it.
Today, SamaCare aggregates and analyzes real-world data from over 2 million prior authorizations across a network of more than 30,000 providers, spanning 97% of U.S. payers. This creates a level of visibility into patient access that has historically not existed. Instead of relying on lagging indicators like claims data, stakeholders can now understand access barriers as they happen, inside provider workflows.
Data alone does not improve patient access. Action does. Over the last 12 months, SamaCare has focused on embedding intelligence directly into the workflows where prior authorizations are created, submitted, and managed.
This includes:
For pharmaceutical market access teams, it also means something new: the ability to move from reactive support programs to targeted, data-driven interventions.
Instead of asking “where are we seeing issues?” after the fact, teams can now identify root causes in near real time and deploy support where it will have the greatest impact. Because the reality is, every delayed prior authorization is a human suffering, instead of starting treatment.
When administrative friction is reduced, the impact is measurable:
These are operational metrics, but they represent something more important: patients starting treatment sooner, staying on therapy, and avoiding the health consequences of delay.
Healthcare is entering a period defined by two opposing forces.
Without intervention, those forces pull in opposite directions.
SamaCare’s approach is to rebalance the system by focusing on the administrative layer, removing the friction that prevents prior authorization decisions from being carried out.
Being named to Fast Company’s Most Innovative Companies list is an incredible honor, but our work is far from done. The administrative barriers that exist between prescription and treatment are still one of the least visible, and most solvable, challenges in healthcare.
Our focus remains the same:
Innovation in healthcare can’t stop at the development of a therapy, it should extend all the way to ensuring that patients actually receive it.
SamaCare has been named No. 14 in the Healthcare category on Fast Company’s 2026 Most Innovative Companies list.
You can view the full list here:
https://www.fastcompany.com/most-innovative-companies/list
Check out why here: https://www.fastcompany.com/91497221/healthcare-most-innovative-companies-2026
We see this recognition as validation of a broader shift happening in healthcare, one that leverages AI to do things AI is good at: simplify complex processes, harness knowledge, and reduce uncertainty to achieve better outcomes.
Prior authorization has become one of the most consequential barriers in modern healthcare. It delays treatment and consumes providers’ time. Too often, prior authorization prevents patients from starting therapies their physicians have already determined are clinically appropriate.
Prior authorization complexity is a systemic issue.
Physicians report that prior authorization contributes directly to delays in care and treatment abandonment. Patients experience those delays as uncertainty, frustration, and in many cases, worsening outcomes.
At its core, the problem is not just complexity, it’s opacity. Each payer has different requirements. Each therapy has different rules. The reasons behind denials or delays are often unclear, inconsistent, and difficult to predict. Denials are even delivered in vastly different formats (one of those sneaky “backend” challenges we had to solve in building SamaCare). For years, this lack of visibility has limited what healthcare stakeholders can actually do to reduce administrative delays that keep patients from treatment.
SamaCare has focused on a simple but powerful idea:
If you can see where patients fall out of the script-to-therapy journey, and why, you can fix it.
Today, SamaCare aggregates and analyzes real-world data from over 2 million prior authorizations across a network of more than 30,000 providers, spanning 97% of U.S. payers. This creates a level of visibility into patient access that has historically not existed. Instead of relying on lagging indicators like claims data, stakeholders can now understand access barriers as they happen, inside provider workflows.
Data alone does not improve patient access. Action does. Over the last 12 months, SamaCare has focused on embedding intelligence directly into the workflows where prior authorizations are created, submitted, and managed.
This includes:
For pharmaceutical market access teams, it also means something new: the ability to move from reactive support programs to targeted, data-driven interventions.
Instead of asking “where are we seeing issues?” after the fact, teams can now identify root causes in near real time and deploy support where it will have the greatest impact. Because the reality is, every delayed prior authorization is a human suffering, instead of starting treatment.
When administrative friction is reduced, the impact is measurable:
These are operational metrics, but they represent something more important: patients starting treatment sooner, staying on therapy, and avoiding the health consequences of delay.
Healthcare is entering a period defined by two opposing forces.
Without intervention, those forces pull in opposite directions.
SamaCare’s approach is to rebalance the system by focusing on the administrative layer, removing the friction that prevents prior authorization decisions from being carried out.
Being named to Fast Company’s Most Innovative Companies list is an incredible honor, but our work is far from done. The administrative barriers that exist between prescription and treatment are still one of the least visible, and most solvable, challenges in healthcare.
Our focus remains the same:
Innovation in healthcare can’t stop at the development of a therapy, it should extend all the way to ensuring that patients actually receive it.
